New strategies to prevent and manage bone complications in cancer

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 1, 2011, Pages 42-44

  Lipton, Allan ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; VITAMIN D; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE DENSITY; BONE DESTRUCTION; BONE DISEASE; BONE METASTASIS; BONE PAIN; BONE REMODELING; BREAST CANCER; DISEASE FREE SURVIVAL; FRACTURE; HIGH RISK PATIENT; HUMAN; HYPERCALCEMIA; HYPERCALCEMIA OF MALIGNANCY; JAW OSTEONECROSIS; KIDNEY FAILURE; MULTIPLE MYELOMA; OSTEOPENIA; OVERALL SURVIVAL; PROSTATE CANCER; SOLID TUMOR;

ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; BONE REMODELING; DIPHOSPHONATES; HUMANS; IMIDAZOLES; RANK LIGAND;

EID: 79951498137     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Coleman RE, Thorpe HC, Cameron D, et al. Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer. The AZURE Trial (BIG 01/04). Paper presented at the 2010 San Antonio Breast Cancer Symposium; Friday, December 10, 2010; San Antonio, Texas.
2. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132-5139.
3. Fizazi, K, Carduccin, MA, Smith, MR, et al. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration resistant prostate cancer. J Clin Oncol (ASCO Annual Meeting Abstracts). 2010;28:Abstract 4507.